The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Estimated Market Size Of The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market In 2026, And How Will Its Value Evolve By 2030?
The sodium glucose cotransporter 2 (sglt2) inhibitors market has shown robust expansion in recent years. Its valuation is expected to rise from $10.96 billion in 2025 to $11.87 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.3%. Historically, this growth can be ascribed to an increase in type 2 diabetes prevalence, unresolved glycemic control requirements, successful clinical trial outcomes, heightened physician recognition, and official regulatory authorizations.
The sodium glucose cotransporter 2 (sglt2) inhibitors market size is projected to experience substantial expansion over the upcoming years, reaching $16.35 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.3%. This anticipated growth during the forecast period stems from factors such as the recognition of cardio-renal benefits, an increasing aging diabetic population, broader reimbursement coverage, the introduction of new drugs, and greater penetration into emerging markets. Key trends expected in this period encompass the expanded application of these inhibitors beyond diabetes, a rise in the adoption of combination therapies, an increase in their use for heart failure indications, enhanced safety profiling, and their wider inclusion in clinical guidelines.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18473&type=smp
Which Important Drivers Are Guiding The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Growth?
The expanding occurrence of diabetes is projected to advance the sodium glucose cotransporter 2 (SGLT2) inhibitor market in the future. Diabetes encompasses a set of metabolic conditions defined by elevated blood sugar levels, stemming from deficiencies in insulin production, its effectiveness, or both. The surge in diabetes instances can be linked to aspects like increased urbanization, psychological stress, environmental contaminants, and insufficient access to medical care. Sodium glucose cotransporter 2 (SGLT2) inhibitors are utilized in diabetes management to reduce blood glucose by impeding glucose reabsorption in the kidneys, thereby promoting its elimination via urine. These inhibitors also provide advantages for cardiovascular and kidney health, establishing them as a crucial choice for managing diabetes and its associated issues. As an illustration, in March 2025, the Office for Health Improvement and Disparities (OHID), a UK-Based English government organization, reported that the recorded prevalence of type 2 diabetes by GPs among adults aged 17 and over in England stood at 7.0% in March 2024, an increase from 6.8% in March 2023. Consequently, the rising incidence of diabetes is propelling the expansion of the sodium glucose cotransporter 2 (SGLT2) inhibitor market.
How Is The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Broken Down By Segment Categories?
The sodium glucose cotransporter 2 (sglt2) inhibitors market covered in this report is segmented –
1) By Type: Invokana, Jardiance, Farxiga Or Forxiga, Suglat
2) By Route Of Administration: Oral Route, Other Route Of Administration
3) By End User: Hospitals, Homecare Settings, Clinics
Subsegments:
1) By Invokana: Generic Invokana (Canagliflozin), Branded Invokana
2) By Jardiance: Generic Jardiance (Empagliflozin), Branded Jardiance
3) By Farxiga Or Forxiga: Generic Farxiga (Dapagliflozin), Branded Farxiga
4) By Suglat: Suglat (Sotagliflozin) For Diabetes, Suglat (Sotagliflozin) For Heart Failure
What Trends Are Influencing The Evolution Of The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?
Leading companies within the sodium glucose cotransporter 2 (SGLT2) inhibitor market are concentrating on developing dual inhibitor therapeutic solutions to enhance patient outcomes and manage blood sugar levels. Such dual inhibitor therapeutic solutions are treatments that concurrently target two distinct sodium-glucose cotransporters (SGLT1 and SGLT2) to improve their efficacy in managing conditions like heart failure and diabetes. For example, in May 2023, Lexicon Pharmaceuticals Inc., a US-based biopharmaceutical company, secured approval from the Food and Drug Administration (FDA) for sotagliflozin, a heart failure treatment. This innovative, first-in-class dual inhibitor of sodium-glucose cotransporters 1 and 2 is a once-daily tablet engineered to lessen cardiovascular death, heart failure hospitalizations, and urgent heart failure visits in adults presenting with heart failure, type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. Its beneficial effects include decreased renal glucose and sodium reabsorption, which subsequently leads to a reduction in preload and afterload, as well as diminished sympathetic activity.
Which Players Are Present In The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Space?
Major companies operating in the sodium glucose cotransporter 2 (sglt2) inhibitors market are Johnson & Johnson Inc., Merck & Co Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Astellas Pharma Inc, Sun Pharmaceutical Industries Ltd, Sumitomo Dainippon Pharma Co Ltd, Taisho Pharmaceutical Holdings Co Ltd, Lupin Limited, Glenmark Pharmaceuticals, Torrent Pharmaceuticals Ltd, Mankind Pharma Ltd, Kissei Pharmaceutical Co Ltd, Kotobuki Pharmaceutical Co Ltd, Lexicon Pharmaceuticals Inc, Novartis AG, Takeda Pharmaceutical Company Limited, Hanmi Pharmaceutical Co Ltd, Chong Kun Dang Pharmaceutical Corp, Mitsubishi Tanabe Pharma Corporation
Get The Full Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Report:
Which Region Is The Top Contributor To The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market By Share?
North America was the largest region in the sodium glucose cotransporter 2 (SGLT2) inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sodium glucose cotransporter 2 (sglt2) inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market 2026, By The Business Research Company
Antidiabetics Market Report 2026
https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report
Mtor Inhibitors Market Report
https://www.thebusinessresearchcompany.com/report/mtor-inhibitors-global-market-report
Kinase Inhibitors Market Report
https://www.thebusinessresearchcompany.com/report/kinase-inhibitors-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model